Guidance Cuts Continue

Investors conclude the long-term plan did not fix the core problem: slower obesity-drug growth and weaker visibility in GLP-1 pricing. Novo Nordisk faces renewed pressure to reduce expectations as Zepbound competition, payer restrictions and pipeline doubts weigh on the stock.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.